Biotech entity
clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention CyPath Lung, the most common co-covered peer. We currently track 1 Biotech story that mention bioAffinity Technologies, Inc., all published on September 5, 2026.
Last mentioned: 6d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention CyPath Lung, the most common co-covered peer. We currently track 1 Biotech story that mention bioAffinity Technologies, Inc., all published on September 5, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 1 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering bioAffinity Technologies, Inc.. Shared-story counts are live from our verified record — not editorial picks.
bioAffinity is leveraging strong clinical data from CyPath Lung, including 92% sensitivity and 99% negative predictive value, to move into post-treatment surveillance. The expansion could broaden the diagnostic's target population beyond initial pulmonary nodule assessment.
bioAffinity Technologies, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
